An artificial pancreatic β-cell based on multipartite zone model predictive control (Multi-Zone-MPC) is evaluated on the UVa FDA-accepted metabolic simulator. Multi-Zone-MPC provides different tunings for the MPC weights based on four regions of glycemia: hypoglycemia, normoglycemia, elevated glycemia, and hyperglycemia. Defining these four zones provides richer control tunings that result in safe and effective control. The controller predictions are based on an average ARX-model that is developed using data collected from a meal response of ten different in silico adult subjects.
INTRODUCTION
Individuals with type 1 diabetes mellitus (T1DM) lack the ability to auto-regulate glucose levels and may suffer from long periods of hyperglycemia without proper treatment with exogenous insulin. This may cause a severe life-threatening condition known as diabetic ketoacidosis (Kitabchi et al., 2006) . Establishing normoglycemia requires a careful balance among the person's daily activities, diet and insulin administration. This balance is not an easy task. Frequent blood glucose measurements must be taken (before and after meals as well as before bed) in order to calculate insulin doses or institute corrective action.
Basal -bolus insulin treatment or intensive insulin treatment can be administered as multiple daily injections (MDI) or via an insulin pump (Skyler, 2005) . Different insulin schedules are suggested for MDI therapy based on the insulin type and duration of action, the daily schedule of the patient, and other medical conditions. Initial doses are calculated based on body weight and are divided into basal and bolus partitions. However, since insulin requirements differ throughout the day, and from day to day, this initial setting needs to be fine tuned to prevent insulin overdose that will result in hypoglycemia or underdose that will result in hyperglycemia (Skyler, 2005) . Insulin therapy using continuous subcutaneous insulin infusion (CSII) has become common practice since its introduction in 1978 (Pickup et al., 1978) . CSII allows a continuous administration of rapid-acting insulin, with patientactivated boluses at mealtimes. This feature introduces a more physiological insulin administration, and therefore better glycemic control than MDI (Danne et al., 2008) . CSII treatment depends on patient decisions and on pre-estimated basal therapy that can result in suboptimal treatment, and therefore a closed-loop algorithm becomes an appealing alternative.
The development of an artificial pancreatic β-cell started nearly four decades ago. These devices can be described as external or internal closed-loop systems that use continuous glucose measurements to manipulate insulin administration, and therefore compensate for the loss of natural abilities for glucoregulation of people with T1DM. Early attempts to design an artificial pancreas were undertaken by Albisser et al. (1973) and Pfeiffer et al. (1974) using both venous blood glucose measurements and intravenous insulin administration. Clemens et al. (1982) used a clamping algorithm with the Biostator® Glucose-Controlled Insulin-Infusion System (GCIIS) and tested it in both animals and humans. Much later, Steil et al. (2004) and Weinzimer et al. (2008) used proportional integral derivative control (PID) for insulin administration.
In recent years, model predictive control (MPC) has been shown to be a promising direction for an artificial pancreas control algorithm (Parker et al., 1996) . MPC is an optimal control algorithm that has been used in the chemical process industries over the last four decades. It is based on a computer control algorithm that uses an explicit process model to optimize the future process response by manipulating future control moves (CM). The MPC concept was developed in the early 1970's and was referred to as identification and command (IDCOM) (Richalet et al., 1976) or as dynamic matrix control (DMC) by engineers from the Shell Company (Cutler and Ramaker, 1979) . Although MPC was originally implemented in petroleum refineries and power plants, it can be found these days in wide variety of application areas including aerospace, food, automotive and chemical applications (Qin and Badgwell, 2003) . Among the reasons for the popularity of MPC are its handling of constraints, it accommodation of nonlinearities, and its ability to formulate unique performance criteria.
The original Zone-MPC algorithm that is described in Grosman et al. (2010) contains a zone of normoglycemia in which the control is not responding to variations in glycemia, and regions surrounding this zone that are controlled with a fixed settings. Zone-MPC showed significant advantages over the "optimal" open-loop therapy by introducing a quiescent control zone where control actions are implemented only when glycemia model prediction deviates out of the safe control zone. Zone-MPC has demonstrated the reduction of control move variability with minimal loss of performance compared to set-point control.
In this work we present an artificial pancreatic β-cell based on Multi-Zone-MPC. The discussed control algorithm is based on four glycemia zones that are regulated with different control tunings. The controller is based on a single model resulting from an average patient ARX-model.
METHODS

AVERAGE MODEL
The response of ten in silico adult subjects, using the FDAaccepted UVa/ Padova metabolic simulator (Kovatchev et al., 2009) , is obtained from a single meal of 75g of carbohydrates. The meal-related insulin bolus is calculated automatically by the simulator based on subject specific insulin to carbohydrate ratio. The continuous glucose monitor (CGM) data is collected for eight hours and twenty minutes (large enough time to incorporate the meal response) and used for individualized identification of part (a) of (1) by linear regression (Ljung, 1999) . Parts (b), and (c) of (1) are kept constant for all subjects. This identification is described in detail in Grosman et al. (2010) 
is the mapped subcutaneous insulin infusion rate, M M g is the mapped carbohydrate (CHO) ingestion input and it represents the absorbed meal's direct influence on the glycemia, I D ' U/h is the insulin infusion rate in deviation variable (I D ' = I D -basal U/h), and M g is the CHO ingestion input. θ is the regression vector, and α, β, and χ are the glucose, the insulin, and meal regressors, respectively.
An initial guess for the average model is obtained by averaging the ten different vectors θ of (1) that are obtained from the identification of part (a) of (1) for each patient separately. Accuracy of the initial average model is illustrated in Fig. 1 (a) and shows limited predictability for some subjects.
Next, the nonlinear optimization in (2) is performed using the fmincon routine (Mathworks Natick, MA) to reduce the sum square of errors (SSE) between the average model's prediction for a period of eight hours and twenty minutes and the raw data collected from each subject.
where PH is the prediction horizon of eight hours and twenty minutes. The optimization is carried out under the following constraints: 1. For stability the roots of the characteristic polynomial, The optimization result is depicted in Fig. 1 (b) and describes a model that captures the general behavior of the 10 subject population. is obtained by a nonlinear optimization that was conducted on the population response. The population responses were obtained for the scenario of one 75g meal scenario given at 1 hour of simulation time accompanied by an insulin bolus that was calculated by each subject insulin to carbohydrate ratio (I:C). 2.2 MULTI-ZONE-MPC MPC optimizes every control sample with a cost function that includes P future process instants, known as the prediction horizon, and M future CM, the control horizon. In each sample, the optimization is repeated using updated process data. However, only the first CM of each optimized sequence is implemented on the process. Process input constraints are included such that the optimum solution prevents future constraint violation.
Guided by medical practice (Nathan et al., 2008 and Moghissi et al., 2009) , the blood glucose concentration can be divided into four zones: zone 1, hyperglycemia, BG > 180 mg/dL; zone 2, near normal glycemia, 140 < BG <180 mg/dL; zone 3, normoglycemia, 80 < BG < 140 mg/dL, and zone 4, danger of imminent hypoglycemia, BG < 80 mg/dL. These zones are included into the cost function used in the Multi-Zone-MPC that is described by the following equation: 
mg/dL for at least a single prediction then Q k and R k are switched to Q k =1 and R k =5000. Otherwise, R k =0.5 for all prediction and Q k switches according to each ' k G  value. The switching is based on glycemia predictions in order to prevent future deviation from the quiescent control zone. The deviations above 140 are all calculated as a deviation to 140, and all deviations below 80 are calculated as a deviation to 80. This introduces a smooth switching out of the quiescent control zone. 
Table 1. Multi-Zone-MPC weights as function of glucose concentration
) the controller is quiescent to deviation in glucose measurements. In zone 4 ( ' 80 k < G  ) the controller is allowed to respond fast to potential hypoglycemia. The control saneness of the four glycemia zones is described by the following:
In this zone, the control actions are constrained to prevent insulin over-dosing. There are at least two good reasons to constrain the control actions in this zone. First, the controller predictions are based on a linear model that is reliable mainly around the linearization point (110 mg/dL). Therefore, inaccurate control action may result in regions that are remote from the linearization point. Second, the control actions are proportional to the deviation of the predicted blood glucose concentration from the bounds of the normoglycemia zone ( 80 ' 140
), and therefore large control moves are anticipated when the predictions are far from these bounds. This can lead to insulin overdosing in the presence of noise or model mismatch.
). In this zone, most of the control actions to avoid hyperglycemia are implemented. This zone is close enough to the upper bound of the normoglycemia zone and therefore a more liberated control action can be implemented.
). In this quiescent zone, the controller does not respond to deviation in glucose measurements. This zone represents the normoglycemia and it is assumed that a subject glycemia can vary between the bounds of this zone without need for regulation.
). In this zone, the weight on the control actions is freed to enable a fast pump shutdown when needed, and by that, preventing pending hypoglycemia.
Comparison of Multi-Zone-MPC and Zone-MPC is conducted on 100 in silico adult subjects following a one meal scenario of 75 g of CHO given at 8pm using the FDA-accepted UVa/Padova metabolic simulator. Control is enabled after two hours of open-loop response. Figure 2 describes the population response to the tested scenario on all 100 UVa/Padova metabolic simulator adult subjects. As can be seen, Multi-Zone-MPC (a) outperforms the Zone-MPC (b) with extended time in the near normal glucose range without any severe hypoglycemic events. , and the histogram of the population glucose distribution (c). In (a) and (b) the zone 80 ≤ G ≤ 140 is depicted by the blue area, and the two black horizontal lines depict G=180 mg/dL and G=60 mg/dL, respectively. The grey area represents the min-max envelope, and the dashed red lines depict the +/-1 standard deviation envelope around the average.
RESULTS
POPULATION RESULT
The LBGI and the HBGI (Kovatchev et al., 2002) are nonnegative quantities that increase when the measurements of low or high blood glucose increases. These indices ranges are between 0 to 100, where low values indicate better glycemia regulation. Using the Multi-Zone-MPC approach reduces significantly the number of hypoglycemic events from 7 to 1, and reduces the LBGI from 0.5 to 0.1, while introducing a lower HBGI and higher glycemic percentage of time between 80 and 180 mg/dL. Magni et al. (2008) introduced the control variability grid analysis (CVGA) for measuring the quality of closed-loop glucose control on a group of subjects. It is a method for visualization of the extreme glucose excursions caused by a control algorithm in a group of subjects, with each subject presented by one data point for any given observation period. A numeric assessment of the overall level of glucose regulation in the population is given by the summary outcome of the CVGA. 
CONTROL VARIABILITY GRID ANALYSIS
DISCUSSION
The CVGA results (Fig. 3 ) and the population results (Fig. 2) show that the Multi-Zone-MPC is able to shift the extremum glycemia values to a lower hyperglycemia without reaching hypoglycemia as evident by fivefold reduction in the LBGI from 0.5 to 0.1 as well as reduction in hypoglycemia events from seven to only one event while still manifesting better lower HBGI and higher percentage of time between 80 to 180 mg/dL. This indicates that the Multi-Zone-MPC can be safe and efficient at the same time. A good illustration of the algorithm features is depicted in Fig.  4 . The initial simulation values that are between 140 ' 180 k < ≤ G  are regulated by rapid control action around the second hour of the evaluation as closed-loop is engaged. Around hour 8 a meal is given and the values of the predicted glycemia enter the 140 ' 180 k < ≤ G  mg/dL zone. This deviation has been handled fast by two relative large boluses. The controller continues to regulate glycemia in a more conservative way when the predictions cross to the next zone ' 180 k > G  mg/dL. Around hour 19 a shutdown of the pump is performed for 60 min to prevent pending hypoglycemia. On the other hand, the Zone-MPC is less efficient in both reducing the hyperglycemia peak and avoiding hypoglycemia with nadir glucose of ~ 65 mg/dL. The addition of multiple glycemia zones provides new degrees of freedom for the control design of the artificial pancreas at the expense of a more complex cost function. The new cost function is a continuous one but not differentiable due to the additional integer switching. However this does not change computation time.
CONCLUSIONS
Multi-Zone-MPC was evaluated on the FDA-accepted UVa /Padova metabolic simulator. The control was based on an average ARX-model that was identified in a novel approach by applying a nonlinear optimization with an initial guess based on ARX-models of different subjects. Multi-Zone-MPC showed significant advantages over Zone-MPC that was presented in previous work, and is shown to be superior to MPC with a fixed setpoint. The separation of the control tuning into four zones allows for both an efficient and safe glycemia regulation. Since fixed tuning was used for the population it is expected that individualized tuning may improve the results further.
